The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of sequential ascending doses of JTZ-951 administered for 15 days in anemic subjects with end-stage renal disease (ESRD) receiving hemodialysis.

Inclusion Criteria:

• Subjects who have ESRD and have been receiving maintenance hemodialysis for at least 12 weeks prior to the Screening Visit
• Body weight (post-dialysis weight) greater than 45.0 kg and a body mass index between 20.0 and 40.0 kg/m2 (inclusive) at the Screening Visit
• Hemoglobin value as defined in the protocol
• Meet the erythropoiesis-stimulating agent (ESA) therapy criteria at the Screening Visit as defined in the protocol

Exclusion Criteria:

• Transferrin saturation and ferritin levels at the Screening Visit as defined in the protocol
• Anemia due to known causes other than chronic kidney disease
• Known history of hyporesponsiveness to ESAs
• Acute coronary syndrome (e.g., myocardial infarction) within 1 year prior to Screening visit